Your browser doesn't support javascript.
loading
Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
Tsoulaki, Olga; Tischkowitz, Marc; Antoniou, Antonis C; Musgrave, Hannah; Rea, Gillian; Gandhi, Ashu; Cox, Karina; Irvine, Tracey; Holcombe, Sue; Eccles, Diana; Turnbull, Clare; Cutress, Ramsey; Archer, Stephanie; Hanson, Helen.
Afiliação
  • Tsoulaki O; St George's University of London, London, UK.
  • Tischkowitz M; Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
  • Antoniou AC; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
  • Musgrave H; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Rea G; Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Gandhi A; Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK.
  • Cox K; Manchester University Hospitals; Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
  • Irvine T; Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
  • Holcombe S; Royal Surrey NHS Foundation Trust, Guildford, UK.
  • Eccles D; Association of Breast Surgery, London, UK.
  • Turnbull C; Department of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Cutress R; Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Hanson H; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Br J Cancer ; 130(12): 2027-2036, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38834743
ABSTRACT

BACKGROUND:

The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.

METHODS:

To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16th of May 2023, with the aim of establishing best practice guidelines.

RESULTS:

Using a pre-workshop survey followed by structured discussion and in-meeting polling, we achieved consensus for UK best practice in use of CanRisk in making recommendations for breast cancer surveillance, eligibility for genetic testing and the input of available information to undertake an individualised risk assessment.

CONCLUSIONS:

Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Testes Genéticos Limite: Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Testes Genéticos Limite: Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article